Wang, Yubin
Hall, Randy A.
Lee, Moses
Kamgar-parsi, Andysheh
Bi, Xiaoning
Baudry, Michel
Article History
Received: 5 June 2017
Accepted: 6 September 2017
First Online: 18 September 2017
Competing Interests
: Several authors are co-founders of NeurAegis, a biotech company directed at developing selective calpain-2 inhibitors for the treatment of acute neuronal death.